Introduction Background Advanced high-grade ovarian cancer (OC) treatment has recently evolved to include novel targeted agents such as PARP-inhibitors. Our survey explores current management of advanced OC in the UK.

Methods Methodology This interim descriptive analysis uses data collected between March-April 2023 from structured interviews with UK-based healthcare professionals (HCPs) involved in secondary care management of advanced OC (OC-NOW).

Results The analysis included 50 OC MDT members. Respondents were mainly based in England (84%; 42/50). Most HCPs (68%; 19/28) used the DESKTOP-III criteria to identify candidates for secondary cytoreduction, with up to 30% of patients considered as eligible in 85% (23/27) of centres. HRD (100%; 41/41) and BRCA1/2 (98%; 40/41) were routinely tested before planning maintenance treatment. Most respondents (90%; 36/40) reported that HRD test results had a turnaround time of 6 weeks. The median number (interquartile range [IQR]) of patients with a BRCA mutation (BRCAmut) was 20.0% (15.0–20.0%), while 25.0% (18.8–30.0%) were HRD (test positive) and BRCA wild type (HRD/BRCAwt), 49.0% (35.0–60.0%) were HRp (test negative) and 10.0% (5.0–11.2%) were HRnd (HR test failure/not determined/inconclusive). Platinum sensitivity was seen as predictive of PARPi maintenance therapy benefit, irrespective of HRD status (table 1).

Conclusion/Implications Conclusion These results provide an update on UK practice in advanced OC. HRD and BRCA1/2 are now routinely assessed with turnaround times on time for maintenance therapy decision making. For Platinum Sensitive OC, PARPi maintenance is typically considered irrespective of HRD status